Document is current
Any future updates will be listed below
-
Authors
Nair, Nisha M.
Hahn, Theresa E. https://orcid.org/0000-0002-3835-8855
Jacobson, Hillary
Holtan, Shernan https://orcid.org/0000-0002-5054-9419
Davila, Marco L.
McCarthy, Philip L. https://orcid.org/0000-0002-9577-3879
Betts, Brian Christopher
Ross, Maureen
Ray, Andrew
McKenzie, Renee
Schofield, Grant
Malek, Ehsan
Herr, Megan M. https://orcid.org/0000-0001-5768-9396
- License Information
-
More Information
Article History
Received: 19 May 2025
Revised: 15 August 2025
Accepted: 5 September 2025
First Online: 18 September 2025
Competing interests
: NMN, TH, MMH, EM, AR and GS: No conflicts of interest to disclose. No company provided funding for this study. MD consultant to BMS and Kite/Gilead. SH research funding from Vitrac Therapeutics and Incyte, clinical trial adjudication to CSL Behring, and consults for Sanofi, Ossium, and MaaT Pharma. BCB research support from CTI BioPharma on the Ad Board for Incyte and has IP licensing for CD83 CAR T: CRISPR Tx 2021-2023. PLM consultant to BlueBird Biotech, BMS, Celegene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda.
: This observational study was approved by the Roswell Park Institutional Review Board and performed in accordance with the Declaration of Helsinki. A waiver of consent was obtained and approved by the Roswell Park Institutional Review Board.
